Statement: compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2. 
Primary_evidence: Adverse Events 1:   Total: 0/3 (0.00%)   Febrile Neutropenia * 0/3 (0.00%)   Neutropenia * 0/3 (0.00%)   Sudden Death * 0/3 (0.00%)   Bacterial Infection * 0/3 (0.00%)   Bronchitis * 0/3 (0.00%)   Sepsis * 0/3 (0.00%)   Lymphoedema * 0/3 (0.00%) Adverse Events 2:   Total: 6/41 (14.63%)   Febrile Neutropenia * 1/41 (2.44%)   Neutropenia * 1/41 (2.44%)   Sudden Death * 1/41 (2.44%)   Bacterial Infection * 1/41 (2.44%)   Bronchitis * 1/41 (2.44%)   Sepsis * 1/41 (2.44%)   Lymphoedema * 1/41 (2.44%)